SMS Pharmaceuticals Limited

NSE SMSPHARMA.NS

SMS Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2024: 16.95%

SMS Pharmaceuticals Limited EBITDA Margin is 16.95% for the year ending March 31, 2024, a 49.02% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

SMS Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2023 was 11.38%, a -50.98% change year over year.
SMS Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2022 was 23.21%, a 4.49% change year over year.
SMS Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2021 was 22.21%, a 6.40% change year over year.
SMS Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2020 was 20.88%, a 3.11% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NSE: SMSPHARMA.NS

SMS Pharmaceuticals Limited

CEO	Mr. Ramesh Babu Potluri
IPO Date	Feb. 28, 2007
Location	India
Headquarters	Plot No. 72
Employees	1,197
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Personal Care Plastics

Description

SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, antiemetic, antiepileptic, antipsychotic, anti-hypertensive, anti-anginal, anti-viral, urinary antispasmodic, and anti-retroviral APIs. It is also involved in the contract research activities. The company also exports its products. SMS Pharmaceuticals Limited was incorporated in 1987 and is based in Hyderabad, India.

Key trends

Past 5 years